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Background: Hypertrophy of cardiomyocytes (CMs) is initially a compensatory
mechanism to cardiac overload, but when prolonged, it leads to maladaptive
myocardial remodeling, impairing cardiac function and causing heart failure. A key
signaling molecule involved in cardiac hypertrophy is protein kinase C (PKC). However,
the role of different PKC isoforms in mediating the hypertrophic response remains
controversial. Both classical (cPKC) and novel (nPKC) isoforms have been suggested
to play a critical role in rodents, whereas the role of PKC in hypertrophy of human CMs
remains to be determined. Here, we aimed to investigate the effects of two different types
of PKC activators, the isophthalate derivative HMI-1b11 and bryostatin-1, on CM
hypertrophy and to elucidate the role of cPKCs and nPKCs in endothelin-1 (ET-1)-
induced hypertrophy in vitro.
Methods and Results: We used neonatal rat ventricular myocytes (NRVMs) and human
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to study the effects of
pharmacological PKC modulators and ET-1. We used quantitative reverse transcription
PCR to quantify hypertrophic gene expression and high-content analysis (HCA) to
investigate CM morphology. In both cell types, ET-1, PKC activation (bryostatin-1 and
HMI-1b11) and inhibition of cPKCs (Gö6976) increased hypertrophic gene expression. In
NRVMs, these treatments also induced a hypertrophic phenotype as measured by
increased recognition, intensity and area of α-actinin and F-actin fibers. Inhibition of all
PKC isoforms with Gö6983 inhibited PKC agonist-induced hypertrophy, but could not fully
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Abbreviations: aPKC, atypical protein kinase C; CM, cardiomyocyte; cPKC, classical protein kinase C; CM, DAG, diac-
ylglycerol; ERK1/2, extracellular signal-regulated kinase 1 and 2; ET-1, endothelin-1; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; HCA, high-content analysis; hiPSC, human induced pluripotent stem cell; hiPSC-CM, human induced
pluripotent stem cell-derived cardiomyocyte; LDH, lactate dehydrogenase; MEK1/2, mitogen-activated kinase kinase 1/2; MTT,
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide; nPKC, novel protein kinase C; Nppa/NPPA, natriuretic peptide
A (rodent/human); Nppb/NPPB, natriuretic peptide B (rodent/human); NRVM, neonatal rat ventricular myocyte; PKC,
protein kinase C; PKD, protein kinase D; proBNP, pro-B-type natriuretic peptide; PS, phosphatidylserine; qRT-PCR,
quantitative reverse transcription PCR; RACK, receptor for activated C kinase.
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block ET-1-induced hypertrophy. Themitogen-activated kinase kinase 1/2 inhibitor U0126
inhibited PKC agonist-induced hypertrophy fully and ET-1-induced hypertrophy partially.
While ET-1 induced a clear increase in the percentage of pro-B-type natriuretic peptide-
positive hiPSC-CMs, none of the phenotypic parameters used in HCA directly correlated
with gene expression changes or with phenotypic changes observed in NRVMs.
Conclusion: This work shows similar hypertrophic responses to PKC modulators in
NRVMs and hiPSC-CMs. Pharmacological PKC activation induces CM hypertrophy via
activation of novel PKC isoforms. This pro-hypertrophic effect of PKC activators should be
considered when developing PKC-targeted compounds for e.g. cancer or Alzheimer’s
disease. Furthermore, this study provides further evidence on distinct PKC-independent
mechanisms of ET-1-induced hypertrophy both in NRVMs and hiPSC-CMs.
Keywords: cardiomyocyte hypertrophy, hiPSC-derived cardiomyocyte, neonatal rat ventricular cardiomyocyte,
endothelin-1, protein kinase C, high content analysis, protein kinase C agonists
INTRODUCTION
Cardiovascular diseases are the most common causes of death
worldwide, accounting for almost one third of all deaths (GBD
2015 Mortality and Causes of Death Collaborators, 2016). Heart
failure, caused most often by a myocardial infarction,
hypertension and cardiomyopathies, affects more than 23
million people globally (Bui et al., 2011). Despite the recent
advances in therapies, heart failure has a poor prognosis as
half of the patients die within 5 years after diagnosis. The
heart adapts to cardiac overload by excessive growth, i.e.
hypertrophy of individual muscle cells, which is characterized
by increased protein synthesis, addition and reorganization of
sarcomeres and changes in gene expression, such as upregulation
of natriuretic peptide A and B coding genes NPPA and NPPB,
respectively (Heineke and Molkentin, 2006; van Berlo et al.,
2013). Cardiac hypertrophy is initially a compensatory
response to normalize the increased pressure to the left
ventricular walls. However, when prolonged it leads to
maladaptive myocardial remodeling, which impairs cardiac
function and can eventually lead to heart failure. As left
ventricular hypertrophy is a key risk factor for the
development of heart failure, several molecular pathways are
under investigation for the potential ability to modulate
hypertrophic growth (Bernardo et al., 2010; van Berlo et al.,
2013; Tham et al., 2015).
One key regulator of cardiomyocyte hypertrophy is protein
kinase C (PKC) (Singh et al., 2017). PKC is a serine/threonine
kinase family consisting of 10 isoforms (Naruse and King, 2000).
By phosphorylating serine and threonine residues of numerous
protein targets, they function as important mediators of many
signaling pathways and contribute to various cellular processes,
including growth, differentiation, proliferation and
tumorigenesis. PKCs are divided into three groups based on
their structure and activation: classical (cPKC; α, βI, βII and
γ), novel (nPKC; δ, ε, η and θ) and atypical (aPKC; ζ and ι/λ)
isoforms. The cPKCs are activated by Ca2+, diacylglycerol (DAG)
and phosphatidylserine (PS), whereas the nPKCs are activated by
DAG and PS independent of Ca2+. In contrast, the aPKCs are
activated independently of Ca2+, DAG and PS. Activation of
cPKCs and nPKCs involves translocation of the enzyme from the
cytosol to the cell membrane, where the second messenger DAG
binds to the so-called C1 domain in the regulatory region of PKC,
which in turn induces a conformational change that leads to
activation (Steinberg, 2008). The C1 domain is also the binding
site for naturally occurring ultrapotent PKC activators such as
phorbol esters and bryostatins (Boije af Gennäs et al., 2011).
Although the same ligands activate many isoforms, not all
isoforms are activated upon same stimuli. Isoform-specific
activation is suggested to occur through interaction of PKC
with isoform-selective receptors for activated C kinase
(RACKs) (Schechtman and Mochly-Rosen, 2001). These
membrane-associated proteins aid individual PKC isoforms to
localize uniquely.
In addition to isoform-selective RACKs, PKC isoforms have
species-, tissue-, and age-specific expression patterns (Singh et al.,
2017). In rat cardiomyocytes (CMs), isoforms α, βI, βII, δ, ε, ζ and
η have been identified, while in human hearts, all isoforms except
γ and θ have been described (Kohout and Rogers, 1993; Rybin
and Steinberg, 1994; Clerk et al., 1995; Shin et al., 2000; Simonis
et al., 2007). Based on differential expression and activation in
hypertrophied and failed hearts and in in vitro experiments with
CMs, particularly isoforms α, β, δ, and ε have been suggested to
mediate CM hypertrophy (Singh et al., 2017). In an attempt to
reveal the roles of individual isoforms, different approaches have
been utilized, such as genetic modulation by transgenic
overexpression (Shubeita et al., 1992; Bowman et al., 1997;
Wakasaki et al., 1997; Takeishi et al., 2000; Braz et al., 2002)
or gene ablation (Roman et al., 2001; Braz et al., 2004; Gray et al.,
2004; Klein et al., 2005; Liu et al., 2009; Song et al., 2015), and
modulation of PKC isoform translocation using RACK binding
or pseudo-RACK peptides (Mochly-Rosen et al., 2000; Chen
et al., 2001; Stebbins and Mochly-Rosen, 2001; Hahn et al.,
2003). The results of these studies have, however, been
conflicting, which might be explained by cross-regulation and
redundancy of PKC isoforms.
PKC has been considered an attractive drug target for various
diseases, including heart diseases, cancer, autoimmune diseases
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and central nervous system diseases (Mochly-Rosen et al., 2012).
Cancer, in particular, has been subject of intensive research.
However, drug development has struggled with designing
isoform-specific and selective PKC activators and inhibitors. In
addition to the difficulties in drug design and synthesis,
understanding that downregulation of PKC protein and thus
decreased PKC activity upon prolonged strong PKC activation is
actually responsible for the tumor-promoting effects of ultrapotent
PKC agonists has only recently led to the reversal of PKC-related
dogma: for the treatment of cancer, PKC activators that do not cause
downregulation should be developed instead of inhibitors (Antal
et al., 2015; Newton and Brognard, 2017). Indeed, only one PKC-
targeted drug has been approved until now: the C1 domain-binding
PKC activator ingenol mebutate was approved for the treatment of
actinic keratosis, precursor of squamous cell carcinoma in 2012, but
has recently been withdrawn from the market due to risk of skin
cancer (Freiberger et al., 2015; European Medicines Agency, 2020).
In addition, another PKC activator, tigilanol tiglate, developed for
treatment of broad range of tumors, has showed promising results in
Phase I study (Panizza et al., 2019). The nature-derived macrocyclic
lactone bryostatin-1 has also been investigated in several clinical
trials against cancer, Alzheimer’s disease and HIV (Wu et al., 2020).
Dialkyl 5-(hydroxymethyl) isophtalates (HMIs) are PKC activators
that bind to the C1 domains of cPKCs and nPKCs at low
micromolar concentrations (Boije af Gennäs et al., 2009). While
the isophthalates, such as HMI-1b11, activate PKC in cellular
context and induce PKC-dependent extracellular signal-regulated
kinase 1/2 (ERK1/2) phosphorylation, they seem to act as partial
agonists instead of full activators (Boije af Gennäs et al., 2009;
Talman et al., 2011; Talman et al., 2013). Together with their easy
synthesis, partial agonism can be considered an advantage for the
isophthalates, as they do not induce PKC downregulation (Sarajärvi
et al., 2018) and thus more closely mimic physiological activation
by DAG.
As PKC activators are being developed for the treatment of many
diseases, it is highly important to characterize their cardiac effects.
The aim of this study was to examine the effects of two different
types of PKC activators, isophthalates and bryostatins, on CM
hypertrophy. As a large part of the research regarding PKC is
based on genetic studies done in mice and most of the
hypertrophy studies have been done in rodents, they may not be
directly applicable to human, and it therefore is important to
compare rodent and human models. Human induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CMs) enable investigation
of human CMs and provide a unique platform to model genetic
cardiomyopathies (Karakikes et al., 2015; Yoshida and Yamanaka,
2017; Brodehl et al., 2019). To compare human and rodent CMs, we
elucidated the role of cPKC and nPKC isoforms in endothelin-1
(ET-1)-induced hypertrophy in vitro both in neonatal rat ventricular
myocytes (NRVMs) and in hiPSC-CMs.
MATERIALS AND METHODS
Compounds and Reagents
The PKC activator HMI-1b11 (bis (1-ethylpentyl) 5-
(hydroxymethyl) isophthalate) was synthesized at the Division
of Pharmaceutical Chemistry and Technology, Faculty of
Pharmacy, University of Helsinki (Finland), as described
previously (Boije af Gennäs et al., 2009) and used at 10 μM
concentration previously shown to bind and activate PKC (Boije
af Gennäs et al., 2009; Talman et al., 2013). The PKC activator
bryostatin-1 was purchased from Sigma-Aldrich (Steinheim,
Germany), the cPKC inhibitor Gö6976 from Merck Millipore
(Burlington, MA, United States), the pan-PKC inhibitor Gö6983
from Stemcell Technologies (Vancouver, Canada), and the
mitogen-activated protein kinase kinase 1/2 (MEK1/2)
inhibitor U0126 from Tocris Bioscience (Bristol,
United Kingdom). The concentrations of the commercially
available PKC and MEK1/2 modulators were chosen based on
reported Ki values and our previous work (Boije af Gennäs et al.,
2009; Talman et al., 2013; Sarajärvi et al., 2018). Endothelin-1
(ET-1), purchased from Sigma-Aldrich, was dissolved in 1%
bovine serum albumin (BSA) in Dulbecco’s modified Eagle
medium (DMEM), while all other compounds were dissolved
in dimethyl sulfoxide (DMSO). The ET-1 concentration of
100 nM was used to stimulate hypertrophy, as described
earlier (Välimäki et al., 2017).
Cell culture reagents were purchased from Gibco (Paisley,
United Kingdom) unless otherwise stated. Collagenase type 2 was
purchased from Worthington Biochemical Corporation
(Lakewood, NJ, United States). BSA (A4919), DMEM,
insulin–transferrin–sodium selenite media supplement (I1884),
pancreatin (P-3292), sodium pyruvate, 3,3′,5-triiodo-L-
thyronine (T3) and all reagents used in cytotoxicity assays
were purchased from Sigma-Aldrich. Growth Factor-Reduced
Matrigel was bought from Corning (Bedford, MA, United States),
and small-molecule inhibitors Y-27632, CHIR99021 and Wnt-
C59 used in hiPSC culture and differentiation were from Tocris
Bioscience (Bristol, United Kingdom). Ultrapure gelatin was
acquired from Merck Millipore.
Cell Culture
Neonatal rat ventricular myocyte (NRVM) cultures were
prepared from 1–3 days old Wistar rats (both sexes) as
described previously (Välimäki et al., 2017; Karhu et al., 2018).
Animals were housed and terminated in accordance with the 3R
principles of the EU directive 2010/63/EU governing the care and
use of experimental animals and following local laws and
regulations. Rats were sacrificed by decapitation and ventricles
were dissected, cut into 5–8 pieces and digested mechanically and
enzymatically by shaking at 600 rpm at 37°C in a digestion buffer
containing 2 mg/ml collagenase type 2, 2 mg/ml pancreatin,
100 mM NaCl, 10 mM KCl, 1.2 mM KH2PO4, 4 mM
MgSO4·6H2O, 50 mM taurine, 20 mM glucose, 100 U/ml
penicillin, 100 µg/ml streptomycin and 10 mM 4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES; pH
6.9) for 1–2 h. The cell suspension was collected and
centrifuged at 160 g for 5 min, whereafter the pellet containing
live cardiac cells was suspended in DMEM/F12 medium
containing 10% fetal bovine serum (FBS), 100 U/ml penicillin
and 100 µg/ml streptomycin. The cells were pre-plated into cell
culturing flasks and incubated at 37°C in a humidified atmosphere
of 5% CO2 for 1–2 h to let non-myocytes attach. The enriched,
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unattached CMs were collected with the medium and seeded on
96-well plates at 40,000 cells/well for cytotoxicity assays or at
30,000–40,000 cells/well for immunofluorescence staining. For
quantitative reverse transcription PCR (qRT-PCR), the cells were
plated on 12-well plates at 500,000 cells/well. For Western
blotting, the cells were plated on 6-well plates at 106 cells/well.
The plating medium was changed to complete serum free
medium (CSFM; DMEM/F12 containing 2.5 mg/ml BSA, 100
units/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml insulin,
5 μg/ml transferrin, 5 ng/ml selenium, 2.8 mM sodium
pyruvate, and 0.1 nM T3) on the following day, whereafter the
cells were let to adapt for 24 h before pharmacological treatments.
All pharmacological treatments were done using CSFM.
HiPSC-CMs were produced from iPS (IMR90)-4 line (WiCell,
Madison, Wisconsin, United States) using a differentiation
protocol described previously (Burridge et al., 2014; Karhu
et al., 2018). Briefly, the hiPSC cultures were maintained in
Essential eight™ medium (E8) on Matrigel (1:50)-coated 6-well
plates and passaged 1:15 approximately every four days using
EDTA. When the cultures were 80–95% confluent,
differentiation was started by adding 6 µM CHIR99021 (day 0)
in RPMI 1640 medium supplemented with B-27 without insulin
(RB-). After 24 h (day 1), the medium was changed to fresh RB-
without CHIR99021. On day 3, fresh RB- containing 2.5 µM C59
was added for 48 h. The cells were fed with RB- on days 5, 7 and 9.
On day 11, metabolic selection of CMs was initiated by changing
RB- to RPMI 1640 without glucose supplemented with B-27 (with
insulin). After 48 h, the cells were fed with freshmetabolic selection
medium. From day 15 onwards, the cardiomyocytes were cultured
in RPMI 1640 supplemented with B-27 (RB+). On day 15 or 17, the
differentiated hiPSC-CMs were dissociated and seeded on gelatin-
coated 96-well plates at 17,500–25,000 cells/well for cytotoxicity
assays and immunofluorescence staining or on gelatin-coated 12-
well plates at 480,000–500,000 cells/well for qRT-PCR in RB+
supplemented with 10% FBS. For Western blotting, the cells were
seeded on 6-well plates at 700,000 cells/well. After letting the cells
attach at least for 48 h, themediumwas changed to serum-free RB+
or treated with test compounds for cytotoxicity assays or Western
blotting. For immunofluorescence staining and qRT-PCR, the
hiPSC-CMs were maintained at least until day 30 before
pharmacological treatments. All treatments were done using
RB+. The differentiation protocol produces 0.5–1.6 × 106 CMs
per one well of a 6-well plate. Only differentiations with >95% pure
cardiomyocytes as assessed by visual inspection of beating cells on
differentiation plates prior to detachment were used. Furthermore,
staining for α-actinin and/or cardiac troponin T were used to
confirm the purity of the CM population (>95% at the time of
imaging). All experiments with hiPSCs were carried out in
accordance with the Finnish Act on the Medical Use of Human
Organs, Tissues and Cells (101/2001). No human tissue samples
were collected for the study. All cell cultures were maintained at
37°C in a humidified atmosphere of 5% CO2.
Cytotoxicity Assays
The cytotoxicity of the compounds was studied using lactate
dehydrogenase (LDH) assay to determine cell membrane integrity
and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide
(MTT) assay to measure mitochondrial metabolic activity, as
described previously (Talman et al., 2011). For cytotoxicity assays,
the cells were exposed to compounds at different concentrations or
to vehicle (0.3% DMSO) for 24 h.
To measure cell membrane integrity, 50 μl of the medium
from each well was transferred to a new 96-well plate and 50 μl of
substrate solution containing 1.3 mM β-nicotinamide adenine
nucleotide, 660 μM iodonitrotetrazolium, 54 mM L (+)-lactic
acid, 280 μM phenazine methosulphate and 0.2 M Tris-HCl
(pH 8.0) was added. After a 30-min incubation at room
temperature (RT) with shaking at 400 rpm for the first 10 min,
formazan formation was stopped by adding 50 μl of 1 M acetic
acid to each well. Absorbance at 490 nm was measured with
Victor2 1420 Multilabel Counter (PerkinElmer, Waltham, MA,
United States). To calculate the cytotoxicity, background
absorbance measured from wells with medium but no cells
was subtracted from all values, after which the spontaneous
LDH release from untreated cells was subtracted and the
values were compared to maximal LDH release of cells lysed
with 0.9% Triton X-100.
To measure the metabolic activity, MTT was added to the cells
at a final concentration of 0.5 mg/ml. After a 2-h incubation at
37°C in a humidified atmosphere of 5% CO2, the medium was
removed, and the formazan crystals were dissolved in 200 μl of
DMSO per well. Absorbance was measured with Bio-Rad plate
reader (Hercules, CA, United States) at 550 nm subtracting the
absorbance at 650 nm as background. The cell viability was
calculated by comparing the absorbance values to the
absorbance of untreated wells. In each independent
experiment, at least two technical replicates were used for each
treatment and the average of the technical replicates was used for
analysis.
Protein Sample Preparation, SDS-PAGE
and Western Blotting
For analysis of PKC isoform expression, CMs on gelatin-coated 6-
well plates were exposed to PKC agonists for 48 h. For analysis of
ERK1/2 phosphorylation, CMs on gelatin-coated 6-well plates
were exposed to PKC inhibitors or MEK1/2 inhibitor for
10–15 min before adding PKC agonists for 30 min. CMs were
then washed two times with PBS and lysed in 150 µl of 1% sodium
dodecyl sulphate (SDS) in 50 mM Tris-HCl (pH 7.5) and
genomic DNA was sheared either by sonication or passing the
lysate through a 25-gauge needle repeatedly. The protein
concentration was measured using the Pierce BCA protein
assay kit (Thermo Scientific) according to manufacturer’s
instructions. Samples were diluted in Laemmli sample buffer
at equal concentrations, boiled for 5 min and stored at ‒20°C until
use. Protein samples (equal amount of protein per lane, 10–25 µg
depending on the experiment) were separated using SDS-PAGE
and subsequently transferred to nitrocellulose membranes.
Membranes were washed with 0.1% Tween 20 in Tris-buffered
saline (TTBS) for 5 min, blocked with 5% nonfat milk powder in
TTBS (milk-TTBS) for 1 h, and incubated with primary
antibodies in milk-TTBS at 4°C overnight. The following
primary antibody dilutions were used: anti-PKCα (ab32376,
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Abcam; 1:1,000), anti-PKCβI (ab195039, Abcam; 1:2,000), anti-
PKCβII (ab32026, Abcam; 1:1,000), anti-PKC-δ (ab182126,
Abcam; 1:5,000); anti-PKCε (ab124806, Abcam; 1:1,000), anti-
PKCη (ab179524, Abcam; 1:2,000), anti-ERK1/2 (sc-94, Santa
Cruz; 1:1,000), anti-phospho-ERK1/2 (9101, Cell Signaling
Technology; 1:1,000) and anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; MAB374, Sigma Aldrich; 1:10,000).
Membranes were then washed with TTBS and incubated with
horseradish peroxidase-conjugated secondary antibodies (goat
anti-rabbit IgG, #7074, Cell Signaling Technology; horse anti-
mouse IgG, #7076; Cell Signaling Technology) diluted 1:2,000 in
milk-TTBS at RT for 1 h. After washing with TTBS, the bands
were visualized by enhanced chemiluminescence using
SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific) and imaged with ChemiDoc MP Imaging System
(Bio-Rad). Western Blots were quantified by measuring the
optical density of the bands using ImageJ. GAPDH was used
as a loading control and all detected bands were normalized to
their corresponding GAPDH bands.
RNA Isolation and qRT-PCR
For gene expression analysis, CMs on gelatin-coated 12-well plates
were exposed to test compounds and ET-1 for 24 h. Cells were lysed
in 500 µl of Trizol reagent (Invitrogen, Carlsbad, CA, United States),
whereafter placed on ice before freezing at ‒80°C where stored
(maximum one month) before RNA isolation. Total RNA was
isolated using the Phase Lock Gel Heavy tubes (Quantabio,
Beverly, MA, United States) according to the manufacturer’s
instructions. RNA samples were treated with rDNase I according
tomanufacturer’s instructions (DNA-free Kit, AM1906, Invitrogen).
RNA concentration and quality were measured by
spectrophotometry with NanoDrop 1000 (Thermo Fisher
Scientific, Waltham, MA, United States). cDNA was synthesized
from 250–500 ng of total RNA in 10 µl reactions with Transcriptor
First Strand cDNA Synthesis Kit (04897030001, Roche, Basel,
Switzerland) according to the manufacturer’s protocol using
random hexamer primers and MJ Mini Personal thermal cycler
(Bio-Rad). The cDNA was diluted 1:10 in PCR grade H2O and
stored at ‒20°C. Commercial TaqMan® Gene Expression Assays
(Thermo Fisher Scientific) for Nppa (Rn00664637_g1), Nppb
(Rn00580641_m1), β-actin coding gene Actb (Mm_00607939_s1),
eukaryotic 18S rRNA (4352930E), NPPA (Hs00383230_g1), NPPB
(Hs01057466_g1) and ACTB (4333762T) were used with
LightCycler® 480 Probes Master reagent (Roche) according to
manufacturer’s instructions to analyze 4.5 µl of the cDNA
dilution in 10 µl reactions on a white LightCycler® 480 Multiwell
Plate 384 (04729749001, Roche) using a LightCycler® 480 Real-
Time PCR System (Roche). Each reaction was run at least in
duplicate and the average value of technical replicates was used
in the analysis. The results were analyzed by the ΔΔCt method by
normalizing first the quantification cycle (Cq) values of the genes of
interest to the average of the Cq values of reference genesActb/ACTB
and 18S rRNA of the same sample and then normalizing the
obtained ΔCq values to the ΔCq values of control sample. No-




For high-content analysis (HCA), the cells on 96-well plates were
exposed to the compounds and ET-1 or vehicle for 24 h or 48 h.
Brefeldin A (Invitrogen) was added to the cells to be stained for pro-
B-type natriuretic peptide (proBNP) 3 h before fixation to block
exocytosis of proBNP-containing vesicles. The cells were washed
twice with phosphate-buffered saline (PBS) and fixed with 4%
paraformaldehyde at RT for 15min and permeabilized with 0.1%
Triton X-100 in PBS at RT for 10 min. Non-specific binding sites
were blocked with 4% FBS in PBS for 45min followed by addition of
primary antibodies diluted in 4% FBS in PBS: sarcomeric α-actinin
antibody (Sigma-Aldrich Cat# A7811, Lot# 128M4812V, RRID:
AB_476766) at 1:200 or 1:600, cardiac troponin T antibody
(Abcam Cat# ab45932, lot# GR3218549-1, RRID:AB_956386) at
1:800 and proBNP antibody (Abcam Cat# ab13115, Lot#
GR3226067-3 RRID:AB_299694) at 1:200. After a 60-min
incubation at RT, the cells were washed 3 × 5min with PBS and
incubated with Alexa Fluor®—conjugated secondary antibodies
(Life Technologies, Eugene, Oregon) at 1:200, Alexa Fluor®
-conjugated phalloidin (Life Technologies) at 1:50 and 4′,6-
diamidino-2-phenylindole (DAPI; Sigma-Aldrich) at 1 µg/ml at
RT for 45 min. The cells were then washed 3 × 5min with PBS
and stored at 4°C in PBS until imaged.
The CellInsight™ CX5 High Content Screening Platform
(Thermo Scientific) was used to image and analyze the cells.
Images were collected using a 10x objective (Olympus UPlanFL N
10x/0.3) with 16–25 sites per well to examine more than 100 cells
in each well. The images were analyzed with the Cellomics
software using two different protocols. The Cellomics
Morphology Explorer BioApplication was used to measure
α-actinin and F-actin staining intensity and to identify and
measure the area and number of α-actinin and F-actin fibers
in the CMs. Briefly, the CMs were identified based on α-actinin
staining and DAPI staining was used to identify the nuclei of the
CMs. Only CMs with one or two nuclei (mono- or binucleated
cells) were included in the analysis. Average intensity of α-actinin
and F-actin within each cell was measured. In addition, α-actinin
and F-actin fibers were identified based on their intensity and
morphology. The settings for fiber recognition were set manually
for each experiment to allow optimal analysis regardless of minor
variations in staining intensities. The fiber recognition and fiber
area analyzed reflect cytoskeletal reorganization: increased fiber
number and fiber area correspond to increased intensity and/or
contrast compared to surrounding pixels, which results in
increased recognition of fibers. The Cellomics Compartmental
Analysis BioApplication was used to analyze the number of
proBNP positive cells. First, the nuclei were identified based
on DAPI staining and the average intensity of proBNP
staining was then quantified from the perinuclear region
defined as an 8-pixel ring around each nucleus. Cells were
classified to proBNP positive and negative cells based proBNP
intensity, and the reference level was set individually for each
experiment. Each experiment included at least two technical
replicates, i.e. two parallel wells of each treatment group. The
average of technical replicates was used in the analysis.
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Statistical Analysis
The results are expressed as mean ± SD of at least three
independent experiments. Each independent experiment was
carried out with cells from individual cell isolations (NRVMs)
or from individual differentiations (hiPSC-CMs). Each
independent experiment, except Western blots, consisted of
technical replicates, of which average was calculated for
statistical analysis to represent n  1. Single outliers of
technical replicates were identified by Grubbs’ test (95%
confidence) and removed from the data. The statistical
analyses were performed using IBM SPSS Statistics 24
software. The one-way analysis of variance (ANOVA) and
Tukey’s post-hoc tests were performed to analyze
concentration-dependent effects of the compounds on
cytotoxicity and cell viability and to analyze the effect of PKC
agonists on expression of PKC isoforms. When unequal variances
were detected by Levene’s test (p < 0.05), Welch’s ANOVA and
Games-Howell post-hoc tests were used. For ERK
phosphorylation, gene expression and HCA data, the statistical
significance of two or three variables: ET-1, PKC activators and
PKC orMEK1/2 inhibitors was evaluated by Univariate ANOVA.
When unequal variances were detected by Levene’s test (p < 0.05),
Kruskall-Wallis test was used. To locate the significantly differing
groups, pairwise comparisons were performed by Student’s t-test
for independent samples after Univariate ANOVA and byMann-
Whitney U test after Kruskall-Wallis test. To be able to perform
the analysis, 1–2% artificial variance was added to the normalized
data of the control group (DMSO). For the analysis of ERK
phosphorylation, the data adjusted to GAPDH (but not
normalized to DMSO) were used for statistical analysis. Values
of p < 0.05 were considered statistically significant.
RESULTS
Effects of PKC Modulators on
Cardiomyocyte Viability
We first investigated the effects of PKC activators and inhibitors
on the viability of CMs. None of the compounds exhibited
significant toxicity in NRVMs or in hiPSC-CMs according to
the LDH assay, cytotoxicity being always less than 10%
(Supplementary Figure S1). The small increase in toxicity
observed with HMI-1b11 treatment at the concentration of
30 µM (6.6 ± 6.0% in NRVMs and 5.4 ± 12% in hiPSC-CMs)
may be due to poor solubility of the lipophilic compound at high
concentration. In MTT assay, the cPKC inhibitor Gö6976
reduced metabolic activity in NRVMs (1 µM, 44 ± 7.1% of
control, p < 0.001; 3 µM, 37 ± 6.7% of control, p < 0.001).
The pan-PKC inhibitor Gö6983 had no significant effect on cell
viability in the MTT assay. Bryostatin-1 increased metabolic
activity at the concentration of 30 nM in hiPSC-CMs (151 ±
18%, p  0.006) while in NRVMs the effect was less obvious.
Of note, bryostatin-1 clearly induced beating of the cells (visual
observation, not shown), which could in part explain the
increased metabolic activity. In addition, there was a trend
toward increased metabolic activity in both NRVMs and
hiPSC-CMs with HMI-1b11 at the concentrations of 1–10 µM,
but not at 30 µM. As both bryostatin-1 and HMI-1b11 activate
PKC, the increase in metabolic activity might originate from
increased PKC activity.
Effects of PKC Modulators on ERK1/2
Phosphorylation
To confirm that the PKC activators indeed activate PKC and
induce PKC-mediated downstream signaling in hiPSC-CMs and
NRVMs, phosphorylation of ERK1/2 was measured by Western
blotting. Representative blots are shown for NRVMs and for
hiPSC-CMs in Figures 1A,C, respectively. In both cell types, a 30-
min treatment with PKC agonists (10 µM HMI-1b11 or 10 nM
bryostatin-1) induced ERK1/2 phosphorylation (Figure 1). In
hiPSC-CMs, the full agonist bryostatin-1 had a greater effect (62-
fold vs. DMSO control, p  0.043) than partial agonist HMI-1b11
(9.8-fold vs. DMSO control, p  0.009), while in NRVMs the
effects of two agonists were similar (11-fold vs. DMSO control,
p < 0.001 for bryostatin-1, p  0.008 for HMI-1b11). The effect of
PKC agonists on ERK1/2 phosphorylation was inhibited by a 15-
min pretreatment with the pan-PKC inhibitor Gö6983 or the
MEK1/2 inhibitor U0126. In contrast, the cPKC inhibitor Gö6976
did not inhibit the response to PKC agonists in NRVMs, but
attenuated the effect of bryostatin-1 on ERK1/2 phosphorylation
in hiPSC-CMs: in the presence of Gö6976, bryostatin-induced
ERK1/2 phosphorylation was 19-fold (p  0.002) compared to
DMSO. These results demonstrate that the PKC activators induce
nPKC and MEK1/2 mediated ERK1/2 phosphorylation in both
CM types.
Effects of PKC Agonists on PKC Isoform
Expression
The expression of PKC isoforms α, βI, βII, δ, ε, and η in hiPSC-
CMs and in NRVMs was confirmed by Western blotting.
Representative blots are shown for hiPSC-CMs in Figure 2A
and for NRVMs in Supplementary Figure S3. As PKC activators
have not previously been studied in hiPSC-CMs, the expression of
PKC isoforms was studied after 48-h exposure to PKC agonists
HMI-1b11 and bryostatin-1. The partial PKC agonist HMI-1b11
(at 10 µM) had no significant effect on the expression of any
isoform, while the full agonist bryostatin-1, even at the low
concentration of 10 nM, downregulated α, βI and δ isoforms
(Figure 2). In particular, the expression of PKCδ was fully
downregulated (0-fold vs. DMSO, p < 0.001), while the
expression of PKCα and PKCβI was decreased 90% (p <
0.001) and 50% (p  0.028), respectively. Bryostatin-1 had no
effect on the expression levels of isoforms βII, ε and η.
Effects of ET-1 on Hypertrophic Gene
Expression
To evaluate the hypertrophic responses of CMs, the expression of
genes encoding natriuretic peptide A (Nppa/NPPA) and B (Nppb/
NPPB) were analyzed. As expected, a 24-h ET-1 treatment
increased hypertrophic gene expression in both cell types
(Figure 3, left panels). ET-1 increased Nppa/NPPA expression
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similarly in both cell types, 4.8-fold (p  0.008) in NRVMs and
4.4-fold (p  0.008) in hiPSC-CMs (Figures 3A,D), while the
increase inNppb/NPPB expression was higher in hiPSC-CMs (21-
fold, p  0.008) than in NRVMs (6.3-fold, p  0.008) (Figures
3G,J). These results show that ET-1-mediated hypertrophic
signaling pathways are functional also in hiPSC-CMs.
Effects of PKC Inhibition on Hypertrophic
Gene Expression
Inhibition of all PKC isoforms by Gö6983 had no significant
effect on the basal Nppa or Nppb gene expression in NRVMs
(Figures 3B,H) but slightly reduced the ET-1-induced expression
of Nppa (20%, p  0.016) and Nppb (33%, p  0.008) (Figures
3C,I). In hiPSC-CMs, the pan-PKC inhibitor Gö6983 had no
significant effect on basal nor ET-1-induced NPPA expression
(Figures 3E,F). However, Gö6983 decreased ET-1-inducedNPPB
expression in hiPSC-CMs by 42% (p  0.016, Figure 3L) and also
the basal NPPB gene expression by 23% (p  0.008, Figure 3K).
These results suggest that PKC is involved in ET-1-induced Nppa
and Nppb signaling in NRVMs.
In contrast to inhibition of all PKC isoforms, cPKC
inhibition with Gö6976 upregulated hypertrophic gene
expression in both cell types (Figures 3H,K). However, for
example, the upregulations of Nppb/NPPB caused by Gö6976
(3.1-fold, p  0.008 in NRVMs and 2.6-fold, p  0.008 in
hiPSC-CMs), were considerably smaller than the changes
induced by ET-1 (6.3-fold in NRVMs and 21-fold in hiPSC-
CMs). In NRVMs, Gö6976 augmented ET-1-induced
hypertrophic gene expression (Nppa, 1.8-fold increase, p 
0.008; Nppb, 2.6-fold increase, p  0.008; Figures 3C,I), while
in hiPSC-CMs cPKC inhibition with Gö6976 attenuated NPPA
response to ET-1 by 20% (p  0.016) and had no effect on
NPPB response (Figures 3F,L). These results demonstrate that
cPKC inhibition is pro-hypertrophic in NRVMs and hiPSCs in
basal conditions. The effect is additive with ET-1-induced
hypertrophic gene expression in NRVMs, but not in
hiPSC-CMs.
FIGURE 1 | Effects of PKC modulators on ERK1/2 phosphorylation. Cells were exposed to cPKC inhibitor (1 µM Gö6976), pan-PKC inhibitor (1 µM Gö6983) or
MEK1/2 inhibitor (10 µM U0126) for 15 min, after which PKC agonists HMI-1b11 (at 10 µM) or bryostatin-1 (at 10 nM) were added for 30 min. (A) Representative
immunoblots for NRVMs; (B) quantification of Western blots expressed as mean + SD of three independent experiments (cardiomyocytes from individual cell isolations)
for NRVMs; (C) representative immunoblots for hiPSC-CMs (day 18–20); (D) quantification of Western blots expressed as mean + SD of three independent
experiments (cardiomyocytes from individual differentiations) for hiPSC-CMs. The expression of phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 were normalized
to GAPDH, after which the ratio was calculated and normalized to DMSO. ***p < 0.001, **p < 0.01, *p < 0.05 vs. DMSO; †††p < 0.001, ††p < 0.01, †p < 0.05 as indicated
(Univariate ANOVA followed by student’s t-test for independent samples). The original full images of immunoblots are shown in Supplementary Figure S2.
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Effects of PKC Activation on Hypertrophic
Gene Expression
In both cell types, the PKC activators increased hypertrophic
gene expression (Figure 3, middle panels). The partial
agonist HMI-1b11 increased Nppb expression by 4.1-fold
(p  0.008) in NRVMs and NPPA expression 1.9-fold (p 
0.008) in hiPSC-CMs. The more potent PKC activator,
bryostatin-1, increased both Nppa/NPPA and Nppb/NPPB
expression in NRVMs (3.5-fold, p  0.008 for Nppa and 11-
fold, p  0.008 for Nppb) and in hiPSC-CMs (2.4-fold, p 
0.008 for NPPA and 5.1-fold, p  0.008 for NPPB). Thus, in
NRVMs, bryostatin-1 upregulated Nppb even more than ET-
1, whereas in hiPSC-CMs the effect of ET-1 on hypertrophic
gene expression was greater than that of any of the PKC-
targeted compounds.
The augmentation of hypertrophic gene expression by PKC
activators was observed also with concomitant treatment with
ET-1 in NRVMs, but not in hiPSC-CMs (Figure 3, right
panels). In fact, bryostatin-1 attenuated the NPPA
expression by 27% (p  0.016) and HMI-1b11 the NPPB
expression by 36% (p  0.008) in the presence of ET-1 in
hiPSC-CMs (Figures 3F,L). These results indicate convergent
but differential regulation of hypertrophic gene expression by
PKC and ET-1 signaling in both CM types.
Inhibition of all PKC isoforms by Gö6983 reversed the
effect of PKC activators on hypertrophic gene expression in
both cell types (Figure 3). On the other hand, the inhibition of
cPKC by Gö6976 tended to augment the effects of PKC
activators in hiPSC-CMs, however, these changes were not
statistically significant (Figures 3E,K). Overall, these results
suggest that the PKC activators induce hypertrophic gene
expression via nPKCs.
Effects of PKC Modulators and ET-1 on
proBNP Expression
To further study the effects of PKC modulators on
hypertrophic response in hiPSC-CMs, expression of proBNP
was studied by immunofluorescence staining and HCA. As the
ERK1/2 pathway is a known downstream mediator of PKC and
ET-1 signaling (Bogoyevitch et al., 1994), effects of the MEK1/
2 inhibitor U0126 were examined in combination with PKC
activators and ET-1. Representative immunofluorescence
images in Figure 4A show a clear increase of proBNP
positive cells in response to ET-1 and an inhibitory effect of
the MEK1/2 inhibitor U0126. This was confirmed by
quantification (Figure 4B): ProBNP was detected in the
perinuclear region in 1.6 ± 2.2% of control hiPSC-CMs,
whereas 18 ± 13% of ET-1-treated hiPSC-CMs were
proBNP positive. None of the PKC-targeted compounds
alone affected the percentage of proBNP positive cells
significantly. However, PKC activator bryostatin-1
attenuated the ET-1-induced proBNP expression to 4.1 ±
1.6% (p  0.114). Interestingly, this effect of bryostatin-1
was abolished with concomitant treatment with both pan-
PKC and cPKC inhibitor. MEK1/2 inhibitor U0126 blocked
ET-1-induced proBNP expression (to 0.6–1.4% proBNP
positive cells) in both control and PKC agonist-treated cells.
These results indicate that in hiPSC-CMs ET-1 signaling is
mediated by MEK1/2, but not through PKC.
Effects of PKC Modulators and ET-1 on
Sarcomeric Proteins
To characterize the phenotypic hypertrophic changes induced by
PKC modulators and ET-1, cardiomyocyte morphology was
FIGURE 2 | Effects of PKC agonists on the expression of PKC isoforms α, βI, βII, δ, ε and η in hiPSC-CMs. The cells were exposed to HMI-1b11 at 10 µM or
bryostatin-1 at 10 nM for 48 h and proteins were detected by Western blotting. (A) Representative blots; (B) quantification of Western blots expressed as mean + SD of
three independent experiments of cardiomyocytes from individual differentiations (day 57–182). Results are normalized to GAPDH and to DMSO control. ***p < 0.001,
*p < 0.05 vs. DMSO control (Welch ANOVA followed by Games-Howell). The original full images of immunoblots are shown in Supplementary Figure S4.
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FIGURE 3 | Effects of endothelin-1 (ET-1) and pharmacological PKC modulation on hypertrophic gene expression in cardiomyocytes. Relative Nppa/NPPA (A–F)
and Nppb/NPPB (G–L) expression in NRVMs and in hiPSC-CMs was measured after 24-h exposure to PKC activators (10 µM HMI-1b11 and 10 nM bryostatin-1),
cPKC inhibitor (1 µM Gö6976), pan-PKC inhibitor (1 µM Gö6983) with or without 100 nM ET-1. Results are expressed as mean + SD of independent experiments with
cardiomyocytes from individual cell isolations or differentiations (n  5 for NRVMs, n  5 for hiPSC-CMs (day 31–52), except for inhibitors combined with ET-1 n  4).
***p < 0.001, **p < 0.01, *p < 0.05 as indicated (Kruskall-Wallis followed by Mann-Whitney U).
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studied by analyzing α-actinin and F-actin fibers using HCA.
Representative fluorescence microscopic images of NRVMs and
hiPSC-CMs are shown in Figures 5, 6, respectively. The most
striking effect was the dramatic increase in F-actin staining
intensity in NRVMs treated with bryostatin-1, ET-1 and Gö6976
(Figures 5, 7B). ET-1 alone increased the average α-actinin and
F-actin intensities in both cell types after a 48-h exposure (Figure 7).
In NRVMs, ET-1 increased α-actinin average intensity by 1.4-fold
(p  0.008) and F-actin intensity 2.1-fold (p  0.008). In hiPSC-CMs,
the changes were slightly smaller; 1.3-fold change in α-actinin (p <
0.001) and 1.4-fold change in F-actin (p  0.032). The hypertrophic
effect of ET-1 was inhibited by U0126 (Figures 7A,B), indicating
that the effect is MEK1/2-dependent in NRVMs (not studied in
hiPSC-CMs). Inhibition of all PKC isoforms also attenuated the ET-
1 response, in particular in hiPSC-CMs (Figures 7C,D). The PKC or
MEK1/2 inhibitors alone had no effect on the average intensity of
α-actinin or F-actin staining apart from a minor decrease (0.9-fold,
p  0.036) in α-actinin intensity in NRVMs after U0126 treatment.
The PKC activators tended to increase α-actinin and F-actin
intensity in NRVMs, bryostatin-1 having a greater effect than
HMI-1b11. For example, bryostatin-1 increased the average
α-actinin intensity by 1.3-fold (p  0.008) and F-actin average
intensity by 3.0-fold (p  0.008).
Although α-actinin and F-actin average intensities were
useful parameters to assess ET-1 response, they were not
able to detect all effects seen for PKC modulators in
hypertrophic gene expression. Therefore, we used HCA also
to recognize α-actinin and F-actin fibers (Supplementary
Figure S6) and to measure the area of recognized fibers
(Figure 8). The ET-1 response was observed also in
α-actinin and F-actin fiber area in NRVMs, but not in
hiPSC-CMs: ET-1 increased the area of α-actinin and
F-actin fibers in NRVMs (1.4-fold, p  0.008 and 1.7-fold,
p  0.151, respectively), but decreased their area in hiPSC-CMs
(0.8-fold, p  0.063 and p  0.029, respectively). The cPKC
inhibitor Gö6976 increased α-actinin and F-actin fiber area
both in NRVMs and in hiPSC-CMs, while the pan-PKC
inhibitor Gö6983 slightly decreased the fiber area in both
cell types. The MEK1/2 inhibitor U0126 had no significant
effect on fiber area (studied only in NRVMs). Bryostatin-1
induced clumping of the NRVMs, which made the fiber
analysis unfeasible. HMI-1b11, in turn, increased the
α-actinin fiber area by 1.4-fold (p  0.008) in NRVMs
(Figure 8A). This effect was reversed by inhibition of all
PKC isoforms or MEK1/2 inhibition. In hiPSC-CMs, PKC
activators had no significant effect on fiber area. However, the
effect of cPKC inhibitor Gö6976 was still observed in the
presence of PKC activators, especially when combined with
ET-1 (Figures 8C,D). The fiber recognition showed similar
trends as the fiber area (Supplementary Figure S6). In
conclusion, these results show that ET-1, PKC activation
and cPKC inhibition cause increased recognition of
α-actinin and F-actin fibers in NRVMs, while in hiPSC-
CMs only the cPKC inhibition show similar effect. These
results also confirm that while not being a high-resolution
analysis of the sarcomeres, HCA is still able to detect general
level cytoskeletal reorganization caused by hypertrophic
stimuli.
FIGURE 4 | Effects of endothelin-1 (ET-1) and pharmacological PKC and MEK1/2 modulation on pro-B-type natriuretic peptide (proBNP) expression in human
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). (A) Representative images of DMSO, U0126 and ET-1 treated hiPSC-CMs stained for DAPI (blue),
cardiac troponin T (green) and proBNP (magenta). (B) Percentage of proBNP positive cells is based on average intensity of proBNP staining in the perinuclear region after
a 24-h exposure to PKC activators (10 µM HMI-1b11 and 10 nM bryostatin-1), cPKC inhibitor (1 µM Gö6976), pan-PKC inhibitor (1 µM Gö6983) and MEK1/2
inhibitor (10 µMU0126) with or without 100 nM ET-1. Results are expressed asmean + SD of four independent experiments with CMs from four individual differentiations
(day 35–48). *p < 0.05 for ET-1 vs. respective CTRL; †p < 0.05 as indicated (Kruskall-Wallis followed by Mann-Whitney U).
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Effects of ET-1 and PKC Inhibitors on
Cardiomyocyte Surface Area
Finally, we measured cell surface area, a standard method to
quantify CM hypertrophy. ET-1 tended to increase the cell
surface area of NRVMs 1.3-fold (p  0.151; Figures 5, 9A),
but not that of hiPSC-CMs (Figures 6, 9B). Furthermore, the
quantification of cell surface area was not feasible for NRVMs
treated with bryostatin-1, which induced NRVMs to clump and
stack up on top of each other (see Figure 5). The PKC activator
HMI-1b11 increased the cell surface area of NRVMs by 1.1-fold
(p  0.032), and this was reversed by MEK1/2 inhibitor
(p  0.036). The hypertrophic effect induced by cPKC
inhibition was observed in both cell types as measured by cell
surface area, although in hiPSC-CMs statistically significantly
only in the presence of ET-1.
DISCUSSION
PKC is associated with pathophysiology of many diseases,
including left ventricular hypertrophy. Initially, different
hypertrophic stimuli, including phorbol esters, α-adrenergic
FIGURE 5 | Effects of endothelin-1 (ET-1) and pharmacological PKC modulation on neonatal rat ventricular myocyte (NRVM) morphology. Representative images
of immunofluorescence stained NRVMs treated with PKC activators (10 µMHMI-1b11 and 10 nM bryostatin-1), cPKC inhibitor (1 µMGö6976), pan-PKC inhibitor (1 µM
Gö6983) and MEK1/2 inhibitor (10 µM U0126) with or without 100 nM ET-1 for 48 h (blue  DAPI, green  α-actinin, red  F-actin). To better visualize morphology, see
Supplementary Figure S5, where brightness and contrast have been adjusted individually for each image.
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agonist and ET-1, were found to activate PKC (Shubeita et al.,
1992; Bogoyevitch et al., 1994). In addition, overexpression of
PKCα and PKCβ were shown to induce hypertrophic gene
expression in CMs (Shubeita et al., 1992; Bowman et al., 1997;
Braz et al., 2002). Later on, altered levels and activation of PKC,
especially isoforms α, β, δ and ε, in hypertrophied and failed
hearts supported the role of PKC in cardiac hypertrophy (Gu and
Bishop, 1994; Bowling et al., 1999; Simonis et al., 2007).
Furthermore, the role of different PKC isoforms in
cardiomyocyte hypertrophy has been studied in rodents
utilizing genetic manipulation and modulation of PKC isoform
expression and translocation (Shubeita et al., 1992; Bowman et al.,
1997; Wakasaki et al., 1997; Mochly-Rosen et al., 2000; Takeishi
et al., 2000; Chen et al., 2001; Roman et al., 2001; Stebbins and
Mochly-Rosen, 2001; Braz et al., 2002; Hahn et al., 2003; Braz
et al., 2004; Gray et al., 2004; Klein et al., 2005; Liu et al., 2009;
Song et al., 2015). For example, using isoform selective
translocation inhibitors, Stebbins and Mochly-Rosen
demonstrated that inhibition of PKCβI or PKCβII
translocation inhibits phorbol 12-myristate 13-acetate (PMA)-
induced hypertrophy in neonatal rat CMs in vitro, suggesting
pro-hypertrophic roles for PKCβI and PKCβII (Stebbins and
Mochly-Rosen, 2001). Mochly-Rosen et al. also showed that
inhibition of PKCε translocation had a dose-dependent
inhibitory effect on normal postnatal myocardial development
in mice, causing lethal cardiac dilatation and CM hypertrophy
(Mochly-Rosen et al., 2000). In addition, a PKCε translocation
activator was shown to increase myocardial growth and
ventricular remodeling with preserved cardiac function and
without increase in CM size, suggesting that PKCε contributes
to physiological hypertrophy and developmental hyperplasia. In
contrast, Song et al. (2015) showed that mice with double cardiac
knockout of PKCδ and PKCε had greater hemodynamic
overload-induced cardiac hypertrophy and dysfunction than
single PKCδ or PKCε knockout mice or wild type mice,
suggesting that these nPKCs actually limit CM growth with
functional redundancy. Overall, these studies have suggested
both classical isoforms βI and βII and novel isoforms δ and ε
to regulate hypertrophic responses.
The conflicting results gained with different methods may be
explained by cross-regulation and redundancy of PKC isoforms.
For example, when one PKC isoform is deleted or inhibited,
another isoform may replace it, as in the case when knockout of
PKCε increased the expression of PKCδ (Klein et al., 2005) or
when silencing of PKCα led to the activation of PKCδ (Naskar
et al., 2014). Furthermore, long-term PKC activation with
ultrapotent agonists, such as phorbol esters, often leads to
down-regulation of PKC protein levels, and thus does not
correspond to the effects of physiological PKC activation
(Newton and Brognard, 2017). Hence, elucidating the role of
PKC and the effects of PKC modulators on CM hypertrophy will
not only facilitate the development of novel therapies to cardiac
diseases, but will also give insight into the cardiac effects of PKC
modulators developed for other applications, such as for the
treatment of cancer. In this study, the role of PKC in ET-1-
induced cardiomyocyte hypertrophy was examined using
pharmacological tools, including two PKC activators acting on
classical and novel PKC isoforms, a cPKC inhibitor and a pan-
PKC inhibitor.
Because PKC isoforms may have divergent roles in different
species (Weeks andMcMullen, 2018) and hiPSC-CMs represent a
unique possibility to study human cardiomyocytes, we used both
hiPSC-CMs and NRVMs in the present study. According to the
present results, PKC modulators have similar effects in both cell
types, suggesting that PKCs have comparable roles in the
hypertrophy of both human and rat CMs. The current
changes in hypertrophic gene expression and phenotypic
parameters quantified with HCA suggest that pharmacological
FIGURE 6 | | Effects of endothelin-1 (ET-1) and pharmacological PKC
modulation on human induced pluripotent stem cell-derived cardiomyocyte
(hiPSC-CM) morphology. Representative images of immunofluorescence
stained hiPSC-CMs (D33) treated with PKC activators (10 µMHMI-1b11
and 10 nM bryostatin-1), cPKC inhibitor (1 µM Gö6976) and pan-PKC
inhibitor (1 µM Gö6983) with or without 100 nM ET-1 for 48 h (blue  DAPI,
green  α-actinin, red  F-actin).
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PKC activators indeed induce CM hypertrophy. Moreover, since
inhibition of all PKC isoforms reversed the effect, the effect was
PKC-dependent and not mediated by another C1 domain-
containing protein (see Das and Rahman, 2014). Furthermore,
the degree of agonism was also reflected in the responses, as the
very potent full agonist bryostatin-1 had greater effects than the
partial agonist HMI-1b11. In contrast to inhibition of all PKC
isoforms, inhibition of cPKCs did not inhibit PKC activator-
induced hypertrophy, but appeared to promote hypertrophy and
aggravate PKC activator-induced hypertrophy. It should be noted
that bryostatin-1 induced downregulation of PKC isoforms α, βI
and δ under the experimental conditions used for phenotypic
analyses in this study, while HMI-1b11 had no effect on PKC
protein levels. Since the responses to bryostatin-1 and HMI-1b11
were similar, it can be speculated that these isoforms may not be
responsible for the pro-hypertrophic effect. Our results thus
suggest that the nPKCs, possibly PKCε and/or PKCη, are
responsible for mediating the PKC agonist-induced
hypertrophic response. Furthermore, cPKCs might have an
anti-hypertrophic role in CMs, so that when cPKCs are
inhibited, the balance is moved toward activation of nPKCs,
which then could mediate the hypertrophic response. This is in
conflict with a previous report showing that knockdown of PKCα
inhibited ET-1-induced hypertrophy (Kerkelä et al., 2002). The
current data suggesting a pro-hypertrophic role of nPKCs also
conflicts with findings reported by Song et al. (2015). However,
the knockout of PKC used by Song et al. (2015) and
pharmacological inhibition of PKC activity used in the present
study are not necessary expected to yield similar biological
responses, as some of PKC-mediated processes are independent
FIGURE 7 | Effects of endothelin-1 (ET-1) and pharmacological PKC modulation on the average intensity of α-actinin and F-actin in cardiomyocytes. Average
intensity of α-actinin and F-actin in NRVMs (A,B, respectively) and in hiPSC-CMs (C,D, respectively) was measured after 48 h exposure to PKC activators (10 µM HMI-
1b11 and 10 nM bryostatin-1), cPKC inhibitor (1 µM Gö6976), pan-PKC inhibitor (1 µM Gö6983) and MEK1/2 inhibitor (10 µM U0126) with or without 100 nM ET-1.
Results are normalized to DMSO control and expressed as mean + SD of independent experiments with CMs from individual cell isolations or differentiations (n  4
for hiPSC-CMs (D32-D49), n  5 for NRVMs except for U0126 n  3). ***p < 0.001, **p < 0.01, *p < 0.05 for ET-1 vs. respective CTRL; ††p < 0.01, †p < 0.05 as indicated
(Univariate ANOVA followed by student’s t-test for independent samples for hiPSC-CMs, Kruskall-Wallis followed by Mann-Whitney U for NRVMs).
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of kinase activity and are instead mediated by protein-protein
interactions (Cameron and Parker, 2010). Furthermore,
compensatory mechanisms activated by catalytic modulation of
PKC activity and knockdown of PKC protein expression are
expected to be different. Furthermore, it is noteworthy that the
cPKC inhibitor Gö6976 also inhibits protein kinase D (PKD),
another known regulator of CM growth. PKD activity is,
however, considered pro-hypertrophic and PKD knockdown
inhibits CM hypertrophy and cardiac remodeling (Fielitz et al.,
2008; Sin and Baillie, 2012), and therefore, the present results
are not likely PKD-mediated. Although PKC activation was
recently shown to have antifibrotic effect in cardiac fibroblasts
suggesting potential strategy to inhibit myocardial fibrosis
(Karhu et al., 2020a), the pro-hypertrophic role of PKC
agonists should be considered.
Although both NRVMs and hiPSC-CMs responded similarly
to PKC modulators, these two CM types differed in their ET-1
signaling. In ET-1-stimulated hiPSC-CMs, the effects of PKC
modulators were abolished, while they were still observed in ET-
1-stimulated NRVMs. Thus, the effects of ET-1 might be
mediated through different signaling pathways in NRVMs and
hiPSC-CMs. In view of the present results, in hiPSC-CMs, ET-1-
signaling passes through other pathways than PKC. However, as
the MEK1/2 inhibitor blocked the ET-1-induced increase in
proBNP expression in hiPSC-CMs, this PKC-independent
signaling could still be mediated through MEK1/2, potentially
by direct activation of ERK-MEK1/2 by Gαq. In contrast, in
NRVMs, the response to ET-1 does not seem to be mediated
neither solely through PKC nor MEK1/2 signaling, since
inhibition of all PKC isoforms or MEK1/2 could not fully
FIGURE 8 | Effects of endothelin-1 (ET-1) and pharmacological PKCmodulation on the area of α-actinin and F-actin fibers in cardiomyocytes. The area of α-actinin
(A,C) and F-actin fibers (B,D) in NRVMs and in hiPSC-CMs was measured after 48 h exposure to PKC activators (10 µM HMI-1b11 and 10 nM bryostatin-1), cPKC
inhibitor (1 µM Gö6976), pan-PKC inhibitor (1 µM Gö6983) and MEK1/2 inhibitor (10 µM U0126) with or without 100 nM ET-1. Results are normalized to DMSO control
and expressed as mean + SD of independent experiments with CMs from individual cell isolations or differentiations (n  4 for hiPSC-CMs (D32-D49), n  5 for
NRVMs, except for U0126 n  3). **p < 0.01, *p < 0.05 for ET-1 vs. respective CTRL; †††p < 0.001, ††p < 0.01, †p < 0.05 as indicated (Kruskall-Wallis followed byMann-
Whitney U, except for α-actinin fiber area in hiPSC-CMs Univariate ANOVA followed by student’s t-test for independent samples).
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prevent the hypertrophic gene expression or the phenotypic
response to ET-1. These results agree with the observation by
Strait et al. (2001) that neither PKCε nor ERK1/2 are necessary for
ET-1-induced hypertrophy. In addition, Ueyama et al. (2000)
showed that dominant negative MEK1 attenuated the response to
different hypertrophic stimuli, including ET-1, phenylephrine,
leukemia inhibitory factor and isoproterenol, but could not fully
inhibit hypertrophic response. Alternatively, ET-1 may act by
activating calcium dependent pathways (calcineurin or calcium/
calmodulin-dependent protein kinase II) or other not fully
characterized hypertrophy-associated pathways, e.g.
phosphoinositide 3-kinase p110γ pathway or other mitogen-
activated protein kinase cascades.
NRVMs and hiPSC-CMs have very different phenotypes.
Although NRVMs do not represent adult CMs, neither do
hiPSC-CMs, which have more structural and functional
similarities to embryonic CMs (Robertson et al., 2013). For
instance, their sarcomeric structure, metabolism and calcium
handling differ from adult CMs. HiPSC-CMs, however, beat
spontaneously and synchronously, express several cardiac
specific genes and proteins and share many
electrophysiological characteristics to adult CMs. Therefore,
while the cell surface area can be used as a phenotypic readout
of hypertrophy in rodent CMs, the flat and rounded phenotype of
hiPSC-CMs makes it less feasible to detect cell growth by
measuring cell surface area, as also shown here. Therefore, we
analyzed hiPSC-CM hypertrophy using HCA to quantify the
expression of proBNP. This method has previously been
developed to screen for ET-1-induced hypertrophic phenotype
of hiPSC-CMs (Carlson et al., 2013) and has also been used to
investigate acute and subacute effects of doxorubicin in hiPSC-
CMs (Karhu et al., 2020b). In the present study, the increased
abundance of proBNP-containing vesicles in response to ET-1
was successfully quantified, but the effects of PKC modulators
that were seen in NPPB mRNA level were not detected with
proBNP staining. Therefore, we quantified α-actinin and F-actin
intensity and fibers. These readouts correlated well with
hypertrophic gene expression in NRVMs, but not in hiPSC-
CMs. The average intensity of α-actinin or F-actin was
increased by ET-1 in hiPSC-CMs, but again, as in the proBNP
assay, effects of PKC modulators were not detected. The only
responses to PKC modulators in HCA were seen in the cell
surface area and fiber analysis, in which cell surface area and
recognition and area of α-actinin and F-actin fibers were
increased by cPKC inhibition. However, no clear
morphological responses to ET-1 or PKC activators were
detected in hiPSC-CMs. Since the morphological changes were
not apparent by visual observation, it can be speculated that while
the hiPSC-CMs seem to exhibit appropriate gene expression
responses to ET-1 stimulation and PKC modulation, their
structural immaturity may prevent the development of clear
morphological hypertrophy and upregulation of sarcomeric
proteins. It is possible that more sensitive analysis using high-
resolution confocal microscopy of sarcomeric structures or
volumetric analysis of hiPSC-CMs could be used to detect
more subtle changes in hiPSC-CM morphology.
CONCLUSION
To our best knowledge, the role of PKC isoforms in
cardiomyocyte hypertrophy has not been investigated
previously using hiPSC-CMs. Our present results show that
PKCs have similar roles in hypertrophy of hiPSC-CMs and
NRVMs: CM hypertrophy can be induced by either activation
of PKC or inhibition of cPKCs, indicating a pro-hypertrophic role
for nPKCs. Furthermore, this study provides further evidence on
PKC-independent mechanisms of ET-1-induced CMhypertrophy
FIGURE 9 | Effects of endothelin-1 (ET-1) and pharmacological PKC inhibition on cardiomyocyte cell surface area. Average cell surface area in NRVMs (A) and in
hiPSC-CMs (B) was measured after a 48-h exposure to PKC activators (10 µM HMI-1b11 and 10 nM bryostatin-1), the cPKC inhibitor Gö6976 (1 µM), the pan-PKC
inhibitor Gö6983 (1 µM) and MEK1/2 inhibitor (10 µM U0126) with or without 100 nM ET-1. Results are normalized to DMSO control and expressed as mean + SD of
independent experiments with CMs from individual cell isolations or differentiations (n  4 for hiPSC-CMs (D32-D49), n  5 for NRVMs, except for U0126 n  3).
**p < 0.01 for ET-1 vs. respective CTRL; ††p < 0.01, †p < 0.05 as indicated (Univariate ANOVA followed by student’s t-test for independent samples for hiPSC-CMs and
Kruskall-Wallis followed by Mann-Whitney U for NRVMs).
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both in NRVMs and in hiPSC-CMs. Moreover, different responses
to PKCmodulators in the presence of ET-1 suggest that dissimilarity
in molecular pathways exist in rat and human CMs (Figure 10).
Importantly, due to the morphological differences between NRVMs
and hiPSC-CMs, similar phenotypic analysis readouts could not be
reliably applied to compare hypertrophic responses between the cell
types, and thus more comprehensive HCA methods are needed to
assess morphological changes occurring in hiPSC-CM hypertrophy.
Our results highlight the differences between the two CM types,
which should be taken into consideration, when applying rodent
studies to human. Furthermore, the present results strengthen the
evidence on pro-hypertrophic effects of PKC activators, which are
currently being developed for various indications such as cancer and
Alzheimer’s disease thus indicating that potent PKC activators
exhibit a significant risk of cardiac adverse effects.
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